uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer
(Thomson Reuters ONE) -
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 06, 2017 (GLOBE NEWSWIRE)
-- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced
the appointment of Steven L. Zelenkofske, D.O., as Chief Medical Officer,
effective immediately. He will report to Matt Kapusta, Chief Executive Officer
of uniQure, and will be based in the Company's Lexington, Massachusetts
facility. Dr. Zelenkofske will succeed Christian Meyer, M.D., Ph.D. and be
responsible for leading all clinical research and development, medical affairs
and related functions at uniQure. Dr. Meyer, who has made significant
contributions to uniQure since joining the company in 2013, will work closely
with Dr. Zelenkofske to ensure a seamless transition.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/7f440f54-659a-497e-88e6-
bc24727bffe0
"Steve is a proven leader with both important industry and clinical practice
experience," said Mr. Kapusta. "He has worked effectively in both large and
small corporate environments and has an accomplished track record leading
clinical research through all phases of development and onto successful
regulatory approvals. As we advance our hemophilia B and Huntington's disease
programs through the clinic, expanding our medical and clinical capabilities in
the United States will become increasingly important, and Steve's broad
experience will be instrumental in helping uniQure deliver our gene therapy
candidates to patients."
Dr. Zelenkofske has nearly 15 years of clinical research experience within the
industry, having previously held leadership positions at AstraZeneca, Sanofi-
Aventis, Boston Scientific, and Novartis Pharmaceuticals. Most recently, Dr.
Zelenkofske served as Vice President and Therapeutic Area Head of
Cardiovascular/Metabolism for AstraZeneca. Prior to joining Astra Zeneca, he
served as Chief Medical Officer for Regado Biosciences, a developer of RNA
aptamer therapies. His clinical experience outside of industry includes serving
on the cardiology and electrophysiology teams with Lehigh Valley Heart
Specialists, Heart Care Group and Cardiology Care Specialists, all in Allentown,
PA, and on the medical staff of Episcopal Hospital in Philadelphia.
Dr. Zelenkofske holds Bachelor of Science and Master of Science degrees from
Emory University and a Doctor of Osteopathic Medicine degree from the
Philadelphia College of Osteopathic Medicine. He conducted his graduate medical
education at the Philadelphia College of Osteopathic Medicine and is board-
certified in internal medicine, cardiology and cardiac electrophysiology.
"I am excited about this very promising opportunity at uniQure," stated Dr.
Zelenkofske. "I look forward to working with the team to advance the clinical
development of the Company's gene therapy programs and to collaborate with
research colleagues to further identify opportunities in the early stage
pipeline."
"On behalf of the company's Board of Directors, leadership team and employees, I
want to thank Christian for his tremendous contributions during the past years
of growth and transition at uniQure," stated Mr. Kapusta. "This includes his
leadership in executing a successful Phase I/II clinical program in hemophilia
B, establishing clinical operations, medical affairs and pharmacovigilance
teams, and achieving regulatory accomplishments for the hemophilia B program
through Breakthrough Therapy and PRIME designations. Christian worked tirelessly
in these areas and this success would not have been possible without his effort
and support."
In connection with Dr. Zelenkofske's offer of employment, uniQure has granted
him 175,000 restricted stock units (RSUs) vesting over three years. One-third of
the RSUs will vest on the first anniversary of Dr. Zelenkofske's start date with
uniQure, and each additional one-third of RSUs will vest on the second and third
anniversary of his start date subject to Dr. Zelenkofske's continued employment
with the Company. This award has been made pursuant to the NASDAQ inducement
grant exception as a component of Dr. Zelenkofske's employment compensation. The
inducement grant is being made as an inducement material to Dr. Zelenkofske's
acceptance of employment with the Company in accordance with NASDAQ listing Rule
5635(c)(4).
About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with
potentially curative results. We are leveraging our modular and validated
technology platform to rapidly advance a pipeline of proprietary and partnered
gene therapies to treat patients with CNS, liver/metabolic and cardiovascular
diseases. www.uniQure.com
uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other
than statements of historical fact are forward-looking statements, which are
often indicated by terms such as "anticipate," "believe," "could," "estimate,"
"expect," "goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar expressions.
Forward-looking statements are based on management's beliefs and assumptions and
on information available to management only as of the date of this press
release. These forward-looking statements include, but are not limited to,
statements regarding the implementation and effects of the Company's new
strategic and organizational changes, the development of our gene therapy
product candidates, the success of our collaborations and the risk of cessation,
delay or lack of success of any of our ongoing or planned clinical studies
and/or development of our product candidates. Our actual results could differ
materially from those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with corporate
reorganizations and strategic shifts, collaboration arrangements, our and our
collaborators' clinical development activities, regulatory oversight, product
commercialization and intellectual property claims, as well as the risks,
uncertainties and other factors described under the heading "Risk Factors" in
uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange
Commission on April 4, 2016. Given these risks, uncertainties and other factors,
you should not place undue reliance on these forward-looking statements, and we
assume no obligation to update these forward-looking statements, even if new
information becomes available in the future.
uniQure Contacts:
FOR INVESTORS:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor(at)uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder(at)uniQure.com
FOR MEDIA:
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone(at)uniQure.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: uniQure N.V. via GlobeNewswire
Bereitgestellt von Benutzer: hugin
" alt="88 Energy Limited: Icewine#2 Operations UpdateDatum: 06.06.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 546528
Anzahl Zeichen: 8029
contact information:
Town:
Amsterdam
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 147 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
uniQure N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
